title: MVP expression in the prediction of clinical outcome of locally advanced oral squamous cell carcinoma patients treated with radiotherapy.
abstract: OBJECTIVE
  To explore the role of Major Vault Protein (MVP) in oral cavity squamous cell carcinoma patients.
  
  
  METHODS
  131 consecutive patients suffering from oral cavity squamous cell carcinoma were included in the study. In the whole series, the mean follow-up for survivors was 123.11 ± 40.36 months. Patients in tumour stages I and II were referred to surgery; patients in stage III-IV to postoperative radiotherapy (mean dose = 62.13 ± 7.74 Gy in 1.8-2 Gy/fraction). MVP expression was studied by immunohistochemistry in paraffin-embedded tumour tissue.
  
  
  RESULTS
  MVP expression was positive in 112 patients (85.5%) and no relation was found with clinic pathological variables. MVP overexpression (those tumours with moderate or strong expression of the protein) was related to insulin-like growth factor receptor-1 (IGF-1R) expression (P = 0.014). Tumour stage of the disease was the most important prognostic factor related to survival. Tumours overexpressing MVP and IGF-1R were strongly related to poor disease-free survival (P = 0.008, Exp(B) = 2.730, CI95% (1.302-5.724)) and cause-specific survival (P = 0.014, Exp(B) = 2.570, CI95% (1.215-5.437)) in patients achieving tumour stages III-IV, in multivariate analysis.
  
  
  CONCLUSIONS
  MVP and IGF-1R expression were related in oral squamous cell carcinoma and conferred reduced long-term survival in patients suffering from advanced stages of the disease.
authors.affiliation: Radiation Oncology Department, Hospital Universitario de Gran Canaria Dr, Negrín, Barranco de La Ballena s/n, Las Palmas de Gran Canaria, CP 35010, Spain. lhenriquez@dcc.ulpgc.es
authors.forename: Luis Alberto
authors.initials: LA
authors.lastname: Henríquez-Hernández
authors.forename: Mercedes
authors.initials: M
authors.lastname: Moreno
authors.forename: Agustín
authors.initials: A
authors.lastname: Rey
authors.forename: Marta
authors.initials: M
authors.lastname: Lloret
authors.forename: Pedro C
authors.initials: PC
authors.lastname: Lara
mesh_terms: D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy*; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000532:radiotherapy*; D011379:Prognosis; D011878:Radiotherapy / Q000379:methods*; D017526:Receptor, IGF Type 1 / Q000096:biosynthesis; D016896:Treatment Outcome; D020394:Vault Ribonucleoprotein Particles / Q000096:biosynthesis*; D000099187:Major Vault Protein
chemical_list: D017526:Receptor, IGF Type 1; D020394:Vault Ribonucleoprotein Particles; D000099187:Major Vault Protein